Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Petersen

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Antimicrobial Agents and Chemotherapy|August 30, 2005
Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolatesPeter J Petersen, Patricia A Bradford
Drugs of Today (Barcelona, Spain : 1998)|January 4, 2006
Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibioticC Hal Jones, Peter J Petersen
Antimicrobial Agents and Chemotherapy|November 26, 2003
In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm modelPornpen Labthavikul, Peter J Petersen, Patricia A Bradford
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489Alexey Ruzin, Peter J Petersen, C Hal Jones
Infectious Disease Reports|January 29, 2014
In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for hospital acquired pneumoniaPeter J Petersen, Margareta Tuckman, C Hal Jones
Diagnostic Microbiology and Infectious Disease|July 31, 2007
In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton brothPeter J Petersen, C Hal Jones, Patricia A Bradford
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infectionsPatricia A Bradford, D Tasha Weaver-Sands, Peter J Petersen
Diagnostic Microbiology and Infectious Disease|March 16, 2010
In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infectionsPeter J Petersen, Alexey Ruzin, Margareta Tuckman, et al.
The Journal of Antimicrobial Chemotherapy|January 25, 2006
In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysisPeter J Petersen, Ponpen Labthavikul, C Hal Jones, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2005
Synthesis and antibacterial activity of 9-substituted minocycline derivativesPhaik-Eng Sum, Adma T Ross, Peter J Petersen, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|August 30, 2005
Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolatesPeter J Petersen, Patricia A Bradford
Drugs of Today (Barcelona, Spain : 1998)|January 4, 2006
Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibioticC Hal Jones, Peter J Petersen
Antimicrobial Agents and Chemotherapy|November 26, 2003
In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm modelPornpen Labthavikul, Peter J Petersen, Patricia A Bradford
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489Alexey Ruzin, Peter J Petersen, C Hal Jones
Infectious Disease Reports|January 29, 2014
In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for hospital acquired pneumoniaPeter J Petersen, Margareta Tuckman, C Hal Jones
Diagnostic Microbiology and Infectious Disease|July 31, 2007
In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton brothPeter J Petersen, C Hal Jones, Patricia A Bradford
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infectionsPatricia A Bradford, D Tasha Weaver-Sands, Peter J Petersen
Diagnostic Microbiology and Infectious Disease|March 16, 2010
In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infectionsPeter J Petersen, Alexey Ruzin, Margareta Tuckman, et al.
The Journal of Antimicrobial Chemotherapy|January 25, 2006
In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysisPeter J Petersen, Ponpen Labthavikul, C Hal Jones, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2005
Synthesis and antibacterial activity of 9-substituted minocycline derivativesPhaik-Eng Sum, Adma T Ross, Peter J Petersen, et al.
Pageof 5